MetaCap

IGC Pharma (IGC) vs Marker Therapeutics (MRKR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Marker Therapeutics (MRKR) has outperformed IGC Pharma (IGC) over the past year, gaining 2.8% versus a loss of 47.5%. Over five years, IGC leads with a -87.6% price change compared with -91.1% for MRKR. IGC Pharma is the larger company by market cap ($19.6 million vs $18.2 million), about 1.1 times the size.

Marker Therapeutics converts more of its revenue into profit, with a net margin of -343.0% versus -560.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IGC-47.50%MRKR+2.83%
+114%+30%-55%
Nov 21, 20251 yearNov 20, 2026
IGC-88.25%MRKR-91.62%
+5%-47%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IGC versus MRKR key metrics
MetricIGCMRKR
Share price$0.168$1.09
Market cap$19.60M$18.17M
1-day change-8.70%-17.42%
YTD return-40.00%-26.85%
1-year return-47.50%+2.83%
5-year return-87.65%-91.14%
EPS (TTM)$-0.07$-0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.27M$3.55M
Revenue growth (YoY)-5.50%-46.19%
Net income (latest FY)$-7.12M$-12.16M
Gross margin48.70%—
Operating margin-585.84%-363.45%
Net margin-560.35%-342.96%
52-week high$0.36$2.46
52-week low$0.08$0.81
Distance from 52-week high-53.33%-55.69%
Analyst consensusnonenone
Avg. price target upside+3471.43%+622.02%
Average volume615.25K711.96K
Shares outstanding116.69M16.67M
Employees705
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRKR has outperformed IGC by 50.3 percentage points over the past year.
  • Marker Therapeutics is more profitable, keeping -343.0 cents of every revenue dollar as net income versus -560.3 cents for IGC Pharma.
  • IGC Pharma grew revenue faster in its latest fiscal year (-5.50% vs -46.19%).

About IGC Pharma

IGC stock →

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

About Marker Therapeutics

MRKR stock →

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

IGC vs MRKR FAQ

Which is bigger, IGC Pharma or Marker Therapeutics?

IGC Pharma (IGC) is larger, with a market capitalization of $19.60M compared with $18.17M for Marker Therapeutics (MRKR).

Which stock has performed better over the past year, IGC or MRKR?

MRKR returned +2.83% over the past 12 months, compared with -47.50% for IGC (price return, excluding dividends). Past performance does not predict future results.

Are IGC Pharma and Marker Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons